ACTRN12615000493549CompletedPhase 4
Efficacy of sequential bismuth based quadruple therapy versus concomitant bismuth based quadruple therapy in treating patients carrying antibiotic resistant Helicobacter pylori strain.
niversity of Western Australia0 sites200 target enrollmentStarted: May 19, 2015Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 18 Years to o limit (—)
- Sex
- All
Inclusion Criteria
- •Patients must fail more than one standard triple therapy, which indicate carrying antibiotic resistant H. pylori strain.
- •If antibiotic sensitivity testing was performed, the strain must be sensitive to Ciprofloxacin and Rifabutin.
Exclusion Criteria
- •free of H. pylori infection, mental disability, pregnancy or lactation in women, known allergy or hypersensitivity to drugs used in study therapy, or current participation with other clinical trials.
Investigators
Similar Trials
Recruiting
Phase 2
Comparing the efficacy of the bismuth-based quadruple therapy containing a high dose of metronidazole with a concomitant regimen containing clarithromycin for eradicating Helicobacter pylori infectioIRCT20200915048726N3Mazandaran University of Medical Sciences200
Recruiting
Phase 4
Comparison of bismuth quadruple therapy with Clarithromycin quadruple therapy in the treatment of Helicobacter pyloriPACTR202304550587833Galpharma200
Active, not recruiting
Not Applicable
Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given x 10 days With Omeprazole in Eradication of Helicobacter pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given x 7 daysMedDRA version: 9.1Level: HLTClassification code 10019375Term: Helicobacter infectionsHelicobacter pylori infectionEUCTR2007-006280-78-IEAxcan Pharma Inc.400
Completed
Phase 3
Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given x 10 days With Omeprazole in Eradication of Helicobacter pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given x 7 daysGastric complaintsHelicobacter infection1001796610004018NL-OMON32065Axcan Pharma16
Active, not recruiting
Phase 1
Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given x 10 days With Omeprazole in Eradication of Helicobacter pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given x 7 daysHelicobacter pylori infectionEUCTR2007-006280-78-FRAxcan Pharma Inc.400